|Chemical and physical data|
|Molar mass||267.67 g·mol−1|
|3D model (JSmol)|
Cenobamate, sold under the brand name Xcopri, is for the treatment of partial-onset seizures in adults.
It was approved for medical use in the United States in 2019.
Cenobamate is a voltage-gated sodium channel (VGSC) blocker. It is a selective blocker of the inactivated state of VGSCs, preferentially inhibiting persistent sodium current. It has been proposed that cenobamate additionally enhances presynaptic release of γ-aminobutyric acid (GABA), thereby increasing inhibitory GABAergic neurotransmission.
The safety and efficacy of cenobamate to treat partial-onset seizures was established in two randomized, double-blind, placebo-controlled studies that enrolled 655 adults. In these studies, patients had partial-onset seizures with or without secondary generalization for an average of approximately 24 years and median seizure frequency of 8.5 seizures per 28 days during an 8-week baseline period. During the trials, doses of 100, 200, and 400 milligrams (mg) daily reduced the percent of seizures per 28 days compared with the placebo group. The recommended maintenance dose, following a titration (medication adjustment) period, is 200 mg daily; however, some patients may need an additional titration to 400 mg daily, the maximum recommended dose, based on their clinical response and tolerability.
- "FDA approves new treatment for adults with partial-onset seizures". U.S. Food and Drug Administration. 21 November 2019. Archived from the original on 22 November 2019. Retrieved 21 November 2019. This article incorporates text from this source, which is in the public domain.
- Younus, Iyan; Reddy, Doodipala Samba (2017). "A resurging boom in new drugs for epilepsy and brain disorders". Expert Review of Clinical Pharmacology. 11 (1): 27–45. doi:10.1080/17512433.2018.1386553. ISSN 1751-2433.
- "Cenobamate FDA Approval Status". Drugs.com. 13 November 2019. Retrieved 22 November 2019.
|This anticonvulsant-related article is a stub. You can help Wikipedia by expanding it.|